# 2021
Lumos Diagnostics Holdings Limited Annual Report

Innovation at the point-of-care

From Our Leaders

Dear Shareholders,

It is truly an honour to write to you in our first annual report as a member of the Australian Securities Exchange (ASX). On 5 July 2021, we rang the bell with overwhelming gratitude for everyone who has been part of our IPO journey — customers, investors, directors, advisors, partners and team members. We joined ASX and welcomed new investors with a humble confidence in our team's ability to create exceptional value for our customers and shareholders as we pursue our mission — moving diagnostic innovation out of the lab and into patient care settings.

It was a historic year for Lumos Diagnostics with the world's pandemic response serving as a dynamic backdrop for the healthcare industry and our customers. The need for high-quality point-of-care (POC) diagnostics and the value of testing with actionable, real-time results evolved from industry jargon to global news to dinner table conversation.

Amid the ubiquitous COVID-19 response measures, the looming global threat of antibiotic resistance continues to grow. At Lumos, we are dedicated to advancing new and disruptive diagnostic technologies that directly address both global-scale healthcare problems.

Lumos is strategically focused on providing comprehensive POC technologies to healthcare providers across a variety of outpatient care settings and medical conditions. Our business model supports a diverse portfolio of POC diagnostics offerings under two business units, Commercial Services and Products, which allows us to optimise our performance as global market conditions ebb and flow. This strategy leverages our core capabilities and infrastructure to provide end-to-end diagnostics solutions for our established and growing Commercial Services client base, as well as for healthcare providers using our Lumos-branded products.

While FY20 was all about integration and transformation, this fiscal year represented strategic action and growth. During FY21, the Lumos team achieved major accomplishments across all aspects of our business — growing sales, expanding our research and development (R&D) programs and manufacturing capacity and establishing global distribution channels. Our increasingly diversified revenue mix reflects a combination of growth across development services, contract manufacturing and product sales. FebriDx®, our flagship product, is a POC diagnostic test for acute respiratory infections that uses a first-of-its-kind dual biomarker technology to rapidly determine if an infection is viral or bacterial. Notably, we achieved key milestones for FebriDx including the completion of the DISRUPT U.S. multicentre clinical trial, submission for U.S. Food and Drug Administration (FDA) 510(k) review, and real world clinical experience in the UK, Canada and Europe.

We are well positioned as an emerging technology leader in the rapidly growing global POC diagnostics industry. Looking ahead, there are significant near and long-term growth opportunities in every segment of our business — POC diagnostic testing, readers and related technologies, contract R&D and manufacturing. During FY22 the Company will leverage its recent investment in expanded manufacturing capacity and capabilities through commercial contract manufacturing, while advancing a promising pipeline of Lumos-branded products including FebriDx, CoviDx™ and ViraDx™.

Leveraging a strong leadership team and an experienced Board has been and continues to be paramount to our success. At Lumos, we are passionate about the products and services we provide, but at the heart of Lumos is the deep understanding that our mission goes well beyond that. It's about placing advanced POC technologies in the hands of front-line healthcare providers so that they can make rapid medical decisions with confidence.

Thank you for joining us on this journey.

Sam Lanyon
EXECUTIVE CHAIR

Rob Sambursky, MD
CHIEF EXECUTIVE OFFICER
EXECUTIVE DIRECTOR